Slide Shows

As August draws to a close, let us take a look back at some of the regulatory headlines from that eventful month and look forward to what September has in store.

As of this writing, the FDA has approved four novel drugs in the month of July, bringing the total number of approvals so far this year to 31.

The ten most valuable companies in the U.S., based on market capitalization, are worth over $11 trillion in total.

In June, as of this writing, two novel drugs have secured the FDA nod – Brexafemme and Aduhelm.

So far this month, only 2 *novel drugs have secured regulatory approval in the U.S. - Johnson & Johnson’s Rybrevant and Apellis Pharmaceuticals’ Empaveli - compared to 6 during the same period last year.

Four novel drugs were approved by the FDA in March taking the tally of new drug approvals in the first quarter of this year to 14. This compares with 11 new drug approvals in the first quarter of 2020. In all, a total of 53 novel drugs were approved last year.

Let us take a look at the new drugs approved in the month of December 2020.

As 2020 draws to a close, it’s time to take a look back at some of the regulatory news that made headlines in December and look ahead at what’s in store for January 2021.

The Food and Drug Administration approved 6 new drugs last month. This compares with 12 new drugs approved in November last year. Now, let us take a look at the new drugs approved in the month of November.

So far, 46 *novel drugs have secured the official stamp of FDA approval compared to 41 during the same period 2019. *Novel drugs are new molecular entities (NMEs) having chemical structures that have never been approved before. Let's take a look at the biotech stocks awaiting FDA decision in December.